title: Discordant neutrophil alkaline phosphatase activity and cytogenetic response in chronic myeloid leukemia treated with alpha-interferon.
abstract: Decreased neutrophil alkaline phosphatase (NAP) synthesis is a classical feature of Philadelphia (Ph) positive chronic phase chronic myeloid leukemia (CML). Whether this aberration is an integral leukemic property of the cell or results from mediation by other factors is unclear. During alpha-interferon (alpha-IFN) based therapy the relationship between Ph chromosome suppression and NAP synthesis was examined. Four categories of response were observed in 19 patients studied sequentially. Significantly, persistent low NAP activity was observed in one patient in complete cytogenetic remission, while a second group of 7 patients demonstrated normal NAP activity in spite of persistence of the Ph chromosome in 100% of metaphases. In the absence of various clinical influences that can modulate NAP activity in chronic phase CML, the results reinforce the observation that the BCR/ABL fusion gene product is not a key factor influencing NAP activity in CML.
authors.affiliation: Department of Haematology, Mater Misericordiae Public Hospital, Brisbane.
authors.forename: D L
authors.initials: DL
authors.lastname: Taylor
authors.forename: A M
authors.initials: AM
authors.lastname: Kerwick
authors.forename: S L
authors.initials: SL
authors.lastname: Elliott
authors.forename: R L
authors.initials: RL
authors.lastname: Rodwell
authors.forename: S J
authors.initials: SJ
authors.lastname: Wright
authors.forename: P V
authors.initials: PV
authors.lastname: Marlton
authors.forename: A R
authors.initials: AR
authors.lastname: Veleba
authors.forename: K M
authors.initials: KM
authors.lastname: Taylor
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D002869:Chromosome Aberrations; D005260:Female; D015321:Gene Rearrangement; D016313:Genes, abl; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000201:enzymology*; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000469:Alkaline Phosphatase; D006918:Hydroxyurea